Celapram

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Celapram

What is Celapram?

Celapram is a medication belonging to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). It is primarily utilized in the management of depression and certain types of anxiety disorders.

Mechanism of Action

The active component in Celapram works by influencing chemical messengers within the brain. Specifically, it targets serotonin, a neurotransmitter associated with mood regulation, sleep, and emotional stability. By slowing the reabsorption (reuptake) of serotonin into nerve cells, the medication increases the availability of this chemical in the spaces between neurons. This process helps to enhance the transmission of nerve impulses, which can lead to an improvement in mood and a reduction in symptoms of emotional distress.

Therapeutic Use

As an antidepressant, Celapram is used to help restore the balance of serotonin in the central nervous system. It is commonly prescribed for:

  • Major Depressive Disorder: To alleviate persistent feelings of sadness, loss of interest, and low energy.
  • Panic Disorder: To help manage and reduce the frequency of sudden episodes of intense fear or discomfort.

Unlike older classes of antidepressants, SSRIs like Celapram are designed to be more selective in their action, focusing specifically on serotonin levels rather than affecting multiple neurotransmitters simultaneously.

Regulatory References

  1. NIH/MedlinePlus

What side effects are possible with Celapram?

Possible Side Effects and Safety Information

The safety profile of Celapram (Escitalopram) is established by government regulatory agencies through clinical trial data and post-marketing surveillance. This information is classified by frequency and body system.

System-Organ Class Very Common (ge 10%) Common (1% - 10%)
Gastrointestinal Nausea Diarrhea, Dry Mouth, Constipation
Nervous System Headache Insomnia, Somnolence, Dizziness, Tremor
Reproductive System Ejaculation Disorder, Anorgasmia, Decreased Libido
General Disorders Fatigue, Increased Sweating

Serious Adverse Reaction Warnings

Official labeling includes serious warnings for conditions such as:

  • Suicidal Thoughts and Behaviors: A Boxed Warning highlights the increased risk in children, adolescents, and young adults (up to age 24), especially at treatment initiation or with dose changes.
  • Serotonin Syndrome: A potentially life-threatening condition associated with fever, agitation, and rapid changes in mental status.
  • Abnormal Bleeding: An increased risk, particularly when Celapram is used concurrently with agents affecting blood coagulation.
  • Hyponatremia: Low sodium levels in the blood, often associated with the Syndrome of Inappropriate Antidiuretic Hormone (SIADH).
  • QT Prolongation: A rare but documented risk of a serious heart rhythm change.

Population-Specific Safety Considerations

  • Elderly Patients: A lower recommended maximum dose is often specified, and this population has an increased documented risk of hyponatremia.
  • Hepatic Impairment: Lower doses are typically recommended for individuals with reduced liver function.
  • Pregnancy: Use late in pregnancy may increase the risk for neonatal poor adaptation symptoms.

Safety-related constraints prohibit the concurrent use of Celapram with Monoamine Oxidase Inhibitors (MAOIs) and Pimozide. Abrupt cessation is discouraged due to the risk of discontinuation symptoms, necessitating a gradual reduction in dose.

Overdose and Emergency Response

Overdose: When to Seek Help

Celapram (citalopram) overdose requires immediate medical attention due to the risk of serious complications, particularly those affecting the heart and nervous system. The maximum recommended dose for most adults is 40 mg per day; higher doses are associated with an increased risk of severe, potentially fatal, heart rhythm abnormalities.

Official Overdose Presentations

Symptoms of a Celapram overdose documented in regulatory reports often include serious cardiovascular and central nervous system effects:

  • Cardiovascular: Fast heart rate (tachycardia), abnormal electrical activity of the heart (QT interval prolongation), and a specific, dangerous type of irregular heart rhythm known as Torsade de Pointes (TdP).
  • Neurological: Seizures, severe shaking (tremor), confusion, agitation, and extreme drowsiness or somnolence.
  • Other: Severe vomiting.

Urgent Medical Action Required

Call emergency services immediately if you or someone else experiences any of the following signs while taking Celapram, as these may indicate a severe overdose or dangerous heart condition:

  • Irregular heartbeat or heart palpitations
  • Shortness of breath
  • Severe dizziness or fainting (syncope)
  • Sudden eye pain, vision changes, or swelling around the eye
  • Symptoms of Serotonin Syndrome, such as high fever, severe agitation, sudden muscle jerks (myoclonus), or confusion.

Patients who are elderly, have existing heart conditions, or are taking other medications that affect heart rhythm are at higher risk for these serious overdose effects. Prompt emergency evaluation is essential to manage potential life-threatening cardiac events and ensure electrolyte balance.

Therapeutic Uses of Celapram

Celapram is a medication used to provide therapeutic support for conditions characterized by symptoms that interfere with daily functioning and emotional dysregulation, aiming to reduce the burden of persistent and distressing symptoms across key therapeutic domains. The medicine is commonly used to help with conditions that include Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and may be applied in contexts of Panic Disorder and Obsessive-Compulsive Disorder (OCD).

The therapy is relevant for easing symptoms in contexts marked by increased worry, pervasive low mood, or acute panic. It is used to address symptom clusters that may become intense or disruptive, such as feelings of hopelessness, anhedonia, and chronic apprehension. This application provides support that helps ease the overall symptom burden, particularly during phases when symptoms become more noticeable. “It supports patients during difficult episodes by easing distress and may assist with supportive symptom management when functional stability is affected.”

Quick Fact: Relief for Persistent Emotional Tension

Celapram is commonly applied for symptomatic support when chronic worry and depressive manifestations interfere with daily comfort. This generally contributes to easing distress during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Celapram (Escitalopram) — Official Regulatory Information

The eligibility for Celapram is strictly defined by official regulatory documents, establishing clear patient criteria for use.


Absolute Contraindications (Prohibited Use)

Celapram is contraindicated (must not be used) for certain patient populations:

  • Patients with known hypersensitivity to escitalopram, citalopram, or any excipients.
  • Patients who are concurrently taking Monoamine Oxidase Inhibitors (MAOIs), including Linezolid, or within 14 days of discontinuing an MAOI.
  • Patients taking Pimozide.
  • Patients with documented QT-interval prolongation or congenital long QT syndrome (as per some regulatory labels).

Age and Condition-Based Restrictions

Official labeling defines specific rules for certain age groups and health conditions:

  • Adults (ge 18 years old) are approved for use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).
  • Adolescents (12 to 17 years old) are approved for MDD (US labeling), though some international labels do not recommend use under 18.
  • Safety and effectiveness for MDD are not established in children under 12.
  • Older Adults (ge 65 years) and patients with hepatic impairment have a restricted maximum recommended daily dose, typically set lower than the standard adult dose.
  • Use is permitted but requires caution in patients with a history of seizures, mania, or angle-closure glaucoma.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Celapram (Escitalopram) interacts with other substances primarily through pharmacodynamic overlap and pharmacokinetic metabolic pathways, as documented in official regulatory labeling. This structure establishes specific constraints and requirements for co-administration.

Formally Contraindicated Combinations

Interaction Type Prohibited Substances
Serotonin Syndrome Risk Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue. A mandatory 14-day separation is required when switching therapies.
Cardiac Risk Pimozide, due to the potential for QT interval prolongation.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Co-administration with other serotonergic agents (such as triptans or St. John's Wort) carries a documented increased risk of Serotonin Syndrome due to additive effects.

Celapram is a modest inhibitor of the CYP2D6 enzyme, which can lead to an increase in the plasma concentration and exposure (AUC) of co-administered CYP2D6 substrate medicines, such as Desipramine. Conversely, inhibitors of CYP3A4 and CYP2C19 (e.g., Omeprazole) may increase the plasma concentration of Celapram itself.

Simultaneous use with drugs that interfere with hemostasis, including NSAIDs and warfarin, is associated with an official increased risk of abnormal bleeding.

Finally, the product label indicates that while no potentiation of alcohol effects was observed in trials, concomitant use with alcohol is not recommended.

Mechanism of Action

Celapram, which corresponds to the compound citalopram, functions as an inhibitor, primarily targeting the Serotonin Transporter (SERT), also known as Solute Carrier Family 6 Member 4 (SLC6A4).

Molecular and Intracellular Pathway

The molecule selectively binds to the SERT protein located on the presynaptic neuronal membrane in the central nervous system. This binding interaction is competitive, resulting in the non-uptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft back into the presynaptic neuron. This action, known as selective serotonin reuptake inhibition, increases the concentration and prolongs the dwell time of 5-HT in the synaptic space.

Downstream and Systemic Consequences

The sustained elevation of synaptic 5-HT leads to increased and prolonged activation of postsynaptic 5-HT receptors. Chronic exposure to increased 5-HT levels is associated with subsequent neuroadaptive changes, including the potential downregulation or desensitization of certain somatodendritic 5-HT1A autoreceptors and an overall potentiation of serotonergic neurotransmission. This biochemical modulation results in system-level physiological changes within the central nervous system that occur over a period of weeks.

Dosage and Administration Information

How to Use Celapram: Official Administration Guidelines

Celapram, containing Escitalopram, is officially administered via the oral route using either the film-coated tablet (available in 5 mg, 10 mg, and 20 mg strengths) or the oral solution. The tablets in 10 mg and 20 mg strengths are scored to allow for precise division.

The medicine is taken as a single daily dose, and its administration is independent of meals, allowing it to be taken with or without food at a consistent time each day, either morning or evening. For adults, the standard starting dose is 10 mg once daily. If a dose adjustment is necessary, the dose may be increased to a maximum of 20 mg daily, but only after a minimum interval of one week has passed since the previous adjustment.

Usage Patterns and Population Adjustments

Official instructions specify mandatory dosing adjustments for certain populations. The maximum recommended dose for older adults (geriatric patients) and those with hepatic impairment is restricted to 10 mg once daily. No adjustment is typically required for patients with mild to moderate kidney impairment. For adolescents (12 years and older) being treated for Major Depressive Disorder, the initial dose is 10 mg, with any dose increase to the 20 mg maximum occurring after a minimum of three weeks.

Treatment often follows an acute phase, necessitating periodic re-evaluation for continued long-term maintenance. Should treatment be discontinued, official procedures mandate a gradual dose reduction (tapering) over a period of at least one to two weeks, as opposed to abrupt cessation.

Recent Clinical Evidence

Celapram: Recent Clinical Evidence

Evidence for Use in Major Depressive Disorder (MDD)

The foundational research for Celapram in Major Depressive Disorder (MDD) is extensive, relying on short-term Randomized Controlled Trials (RCTs). These studies tracked patient-reported outcomes describing perceived discomfort and observed adult outpatients, including older adults. Research describes patterns of symptom evolution measured over the acute treatment phase (typically six to twelve weeks). Studies explored patterns related to standardized measurements of symptom severity and examined the timing and rates of the return of symptoms. These findings contribute to the broader evidence landscape related to monitoring symptom patterns over time.

Evidence for Use in Generalized Anxiety Disorder (GAD)

Celapram was evaluated in numerous controlled trials for Generalized Anxiety Disorder (GAD), using specialized scales to examine outcomes related to chronic worry and anxiety severity. Studies monitored the stability of symptom patterns over periods of up to a year, describing patterns related to preventing the return of anxiety symptoms.

Evidence for Use in Panic Disorder and Obsessive-Compulsive Disorder (OCD)

Research examined the use of Celapram in Panic Disorder (PD) through placebo-controlled RCTs, focusing on outcomes related to episodic changes in the frequency of panic attacks. Celapram was studied for Obsessive-Compulsive Disorder (OCD) using dedicated RCTs to examine the severity of obsessions and compulsions.

Key Evidence Gaps and Areas of Uncertainty

Comprehensive functional recovery outcomes extending beyond one year are not as consistently characterized as short-term symptom scores. Comparative evidence is lacking to definitively benchmark Celapram against all available active agents. Data for certain groups remain insufficient, particularly for patients with complex comorbidities, as these populations were frequently excluded from key clinical trials. The evidence quality varies across studies, and the interpretation of findings may differ from the specific populations studied in the controlled trial environment.

Key Studies & References

  1. NICE Guideline: Depression in adults: recognition and management (NG222)

Frequently Asked Questions (FAQ)

Common questions about Celapram (FAQ)

Q: What is the main difference between Celapram and other similar medications?

The active ingredient, Escitalopram, is a purified form (the S-enantiomer) of the related compound Citalopram. This refinement is described in official documents as giving it higher selectivity in how it inhibits the serotonin transporter.

Regulatory documents focus on the drug's approved uses and do not typically offer comparative statements regarding the clinical effects of one medication against all others in the same class.


Q: How long does it usually take to notice any effect from Celapram?

The physiological changes in the brain's serotonin system begin to occur over a period of weeks, not immediately. Changes related to symptom evolution may be observed over several weeks or longer, with maximum effectiveness potentially reached after two to three months of treatment.


Q: Is Celapram considered a long-term or short-term treatment?

Celapram is officially indicated for both acute treatment of symptoms and for the maintenance phase of approved conditions. The acute phase typically lasts several weeks, but treatment often continues longer, as the purpose of maintenance treatment is to address the potential for symptoms to return.

Official guidelines state that treatment for maintenance can continue for several months or more, depending on a patient's situation.


Q: Can Celapram cause weight changes, like gain or loss?

Yes, regulatory documents list both an increase in weight and loss of appetite (known as anorexia) as possible side effects. Official guidelines mention the importance of monitoring weight and height, particularly for adolescents.


Q: Is it common to feel more anxious when first starting Celapram?

Some regulatory documents indicate that certain patients, particularly those being treated for Panic Disorder, may experience increased anxiety, restlessness, or agitation when initiating treatment.

This initial reaction is commonly reported to lessen within the first two weeks of use.


Q: Are there any specific foods or drinks to avoid while taking Celapram?

The official product information specifically states that concomitant use with alcohol is not recommended. Beyond alcohol, the regulatory labels do not typically list restrictions on foods or non-alcoholic drinks.


Q: What happens if a dose of Celapram is missed?

Regulatory guidelines provide specific administrative information concerning missed doses.

The official caution is noted against doubling the dose to compensate for a forgotten one.


Q: Is it safe to take herbal supplements or vitamins alongside Celapram?

The use of other serotonergic agents, including the herbal remedy St. John’s Wort, is specifically associated with an increased risk of Serotonin Syndrome. No general warnings are provided for routine vitamins; however, the label suggests consultation with a qualified healthcare professional regarding all combinations.


Q: What are the possible concerns about taking Celapram during pregnancy or breastfeeding?

Use late in pregnancy may increase the risk for neonatal poor adaptation symptoms in the newborn. Furthermore, the active substance has been detected in breast milk.

Official information notes that infants exposed via breast milk are monitored for signs such as excess drowsiness, restlessness, or changes in feeding and weight gain.


Q: Can Celapram affect the ability to drive or operate machinery?

Any psychoactive medicine may impair judgment or skills. Regulatory documents note that potential risks exist concerning a patient’s ability to drive a car or operate machinery safely.

The product label states that caution is necessary until the individual's response to the medication is established.


Q: Are there generic versions of Celapram available, and are they the same?

Yes, regulatory bodies in various countries have approved generic versions of the active ingredient, Escitalopram. These generic products are required to demonstrate bioequivalence to the original Celapram, meaning they are considered the same in terms of quality and performance for patient use.


Q: What is the official definition of the primary condition Celapram is used to treat?

Official regulatory labels define Major Depressive Disorder (MDD) as a prominent and relatively persistent depressed or irritable mood that affects a person's daily life.

This definition typically includes having a specific number of related symptoms for a defined period of time.


Q: Are there any specific blood tests required while taking Celapram?

Routine specific blood tests are not generally mandated in the label for every patient taking this medication. However, Celapram carries a documented risk of causing low sodium levels in the blood, known as Hyponatremia. This risk means that testing of serum sodium levels may be necessary for at-risk populations, such as older adults.


Q: Is there evidence of Celapram affecting memory or concentration?

Difficulty concentrating and memory impairment are listed as reported side effects, which may also be symptoms of low sodium levels (Hyponatremia). The official label indicates that monitoring for these effects may be required.


Q: Why is Celapram often started at a low amount and then increased?

The official practice of starting with a low dose and gradually increasing the amount (known as titration) is designed to help reduce the likelihood of dose-related adverse effects. This approach helps patients adjust to the medicine and minimizes potential initial side effects, such as increased anxiety symptoms.


Q: Can Celapram cause a temporary increase in headaches?

Headache is listed in official documents as a very common side effect. While the label does not explicitly define the headache as 'temporary,' many side effects linked to this drug class are commonly reported to be most noticeable when treatment is first initiated.


Q: Are there differences in reported side effects between men and women taking Celapram?

Official labeling distinguishes between the sexual side effects reported by men and women. For instance, ejaculation disorder is listed for men, while anorgasmia (difficulty achieving orgasm) is listed for women. This distinction indicates differences in how sex-specific side effects were reported during studies.


Q: What is the connection between Celapram and changes in appetite?

Changes in appetite are a documented side effect reported in official documents. Clinical trials noted both increased appetite and reduced appetite as possible outcomes of taking Celapram.


Q: Do studies suggest Celapram can be used with psychotherapy?

For some of its approved uses, regulatory documentation notes that pharmacotherapy (treatment with medicine) is often part of an overall comprehensive therapeutic strategy. This suggests that Celapram may be used in conjunction with other forms of treatment, such as psychotherapy.


Q: Can Celapram cause sensitivity to sunlight?

Increased sensitivity of the skin to sunlight, a condition known as photosensitivity, is a reported side effect. Official caution is advised regarding sun exposure.

How should Celapram be stored and disposed of?

How to Store and Dispose of Celapram?

Celapram requires strict adherence to official storage and disposal protocols documented by regulatory bodies.

Item Official Storage/Disposal Requirement
Storage Temperature Must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F) [FDA Label].
Environment & Protection Protect the medication from moisture, excess heat, and freezing [MedlinePlus; Safety Data Sheet]. Must be kept in the original, tightly closed container [MedlinePlus].
Child Protection Mandatory requirement to keep the product out of the sight and reach of children and to lock safety caps [MedlinePlus; Safety Data Sheet].
Disposal Instructions Disposal should prioritize drug take-back programs or mail-back options. If unavailable, mix the product with an unappealing substance (e.g., dirt, coffee grounds) and seal it for household trash.
Environmental Rule Do not flush the medicine down the toilet or release it into the environment, as mandated by official disposal guidance [FDA; Safety Data Sheet].

These instructions define how the product must be stored, protected, handled, and ultimately discarded to ensure product stability and public safety, without exception.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Celapram found in:

A-Z Index: